Navigation Links
AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Date:11/24/2009

    Primary efficacy endpoint has been met for patients with advanced-stage
    or recurrent endometrial cancer

QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer. In a personalized health care approach, the study selected patients with tumors expressing luteinizing hormone-releasing hormone (LHRH) receptors, the key element in the targeting mechanism of AEZS-108. Under the coordination of Prof. Gunter Emons, MD, Chairman of the Department of Obstetrics & Gynaecology at the University of Gottingen, Germany, this open-label, multi-center and multi-national Phase 2 study AGO-GYN 5, is being conducted by the German AGO Study Group (Arbeitsgemeinschaft Gynakologische Onkologie/Gynaecological Oncology Working Group; www.ago-ovar.de), in cooperation with clinical sites in Europe.

Preliminary Results

A preliminary evaluation has shown that the study AGO-GYN 5 met its predefined primary efficacy endpoint of 5 or more responder patients with endometrial cancer. The study is currently ongoing, and responders, as well as patients with stable disease after completion of treatment with AEZS-108, will be followed to assess the duration of progression-free survival and, ultimately, overall survival. Detailed analyses of the study results will be presented at forthcoming scientific conferences.

Juergen Engel, Ph.D., President and Chief Executive Officer at AEterna Zentaris stated, "We are pleased with the progress of this Ph
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... VIENNA, Austria, October 23 GlaxoSmithKline Biologicals,S.A. ... execution of a,collaboration agreement granting GSK exclusive ... at treating Alzheimer,s by,targeting beta-amyloid., As ... exclusive rights to develop,and commercialise two Alzheimer,s ...
... Jersey, October 23, Rosetta Genomics Ltd. (Nasdaq: ROSG ... and therapeutics, today,announced that it will present at ... Cancer". The event will take place from,October 30 ... poster presentation, titled "MicroRNA-based identification of tumor,origin", will ...
... Oct. 23 Solos Endoscopy, Inc. (Pink,Sheets: SNDY) ... detection,through the use of mammary ductoscopy was a ... 94th Annual American College of Surgeons Clinical,Congress in ... of the,ductal lobular anatomy of the breast and ...
Cached Biology Technology:GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 2GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 3Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 2Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 3Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress 2
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has ... Market Overview" report to their offering. , ... that an individual is who she/he is claiming to be, ... a person,s unique physical characteristics, such as fingerprint, hand or ...
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... delay the onset of Alzheimer,s disease, but none are able ... detection the key to Alzheimers patients maintaining a good quality ... a new device developed by the Georgia Institute of Technology ... inexpensive test that could be administered as part of a ...
... experiments was to test a computer algorithms ability to ... and classify them according to different contexts and individual ... 14 Hungarian sheepdogs (Mudi breed) in six different situations: ... were recorded with a tape recorder before being transferred ...
... plant material and burn it. If managed well most of ... by the growing plants, and so have a low impact ... the growing plants could be used to help solve other ... from the Department of Energy and Environment at Chalmers University ...
Cached Biology News:Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3Biomass production -- careful planning can bring many benefits 2
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. pombe) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... The recent sequencing of Salmonella genomes has ... Typhimurium ORFmer PCR* primer pairs. The S. ... a single chromosome (4,857,432 bp; 4,440 ORFs) ... ORFs). These ORFmers from Sigma-Genosys have been ...
... own microplate stacker system, offers fast and ... host devices:, , Ultra Evolution , SAFIRE ... and SpectraFluor Plus , LS Series of ... supporting a wide range of detection and ...
... balance makes your life easier. It offers a wide ... for one balance. *Instruments supported: ... UMX, AG, XS, XP, PR, SR, PG-S, PG, SG, ... User guidance on ...
Biology Products: